earnings
confidence high
sentiment positive
materiality 0.85
Indivior raises FY 2025 guidance after Q2 beat; SUBLOCADE revenue up 9%
Indivior Pharmaceuticals, Inc.
2025-Q2 EPS reported
$0.52
revenue$568,000,000
- Q2 total net revenue $302M (+1% YoY); net income $18M ($0.14 EPS); non-GAAP diluted EPS $0.51.
- SUBLOCADE net revenue $209M (+9% YoY, +19% vs Q1'25); U.S. SUBLOCADE $195M (+9% YoY).
- FY 2025 guidance raised: net revenue $1.03B-$1.08B (prior $955M-$1.025B); adjusted EBITDA $275M-$300M (prior $220M-$260M).
- Adjusted EBITDA Q2 $88M vs $93M Q2'24; cash and investments $538M at Q2 end.